UW Medicine’s Memory and Brain Wellness Center treated its first patient with the new Alzheimer’s drug, lecanemab, on Dec. 1. The drug has been shown to reduce cognitive decline in patients with early Alzheimer’s disease.
Doug Davidson, of Mount Vernon, Wash., was the first patient to receive the intravenous drug at UW Medicine.
“I’m pleased that Harborview Medical Center is one of the first West Coast hospitals to administer the IV infusion treatment to our qualifying patients,” said Dr. Thomas Grabowski, a professor of radiology and neurology at the University of Washington School of Medicine. A behavioral neurologist, Grabowski is medical director of the Memory and Brain Wellness Center, based at Harborview.
